Actively Recruiting
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-02-18
176
Participants Needed
1
Research Sites
90 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
CONDITIONS
Official Title
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before the trial
- Aged between 18 and 75 years old at consent, any gender
- Participants and partners agree to use effective contraception and avoid pregnancy during and one month after the study; female participants must have negative pregnancy tests and not be breastfeeding
- Clinically diagnosed with non-segmental vitiligo during screening
- Agree to stop all vitiligo treatments and cosmetic products with therapeutic effects during the study
You will not qualify if you...
- Diagnosed with segmental, mixed, or undifferentiated vitiligo or other skin pigmentation disorders
- Facial vitiligo lesions with white hair covering more than 33% of the area
- Presence of active skin lesions or infections during screening or baseline that could affect treatment or evaluation
- History of related infections or communicable diseases
- Known or suspected immunosuppression
- Tuberculosis or latent tuberculosis infection
- Positive for HIV, syphilis, hepatitis B or C infections
- Current or past malignant tumors
- Abnormal thyroid function, recent thrombotic disease, or cardiovascular/cerebrovascular event requiring hospitalization within 12 months
- Serious abnormalities in major body systems including cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, musculoskeletal, skin, sensory, endocrine, or blood systems
- Pregnant, breastfeeding, or planning pregnancy during the study
- Known allergy to the study drug or its components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dermatology Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China, 250022
Actively Recruiting
Research Team
H
Hui Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here